Human LR3 IGF-I (Receptor Grade)
The Eagle Bioscience’sHuman LR3 IGF-I (Receptor Grade) is for research use only and not to be used for diagnostic procedures.
IGF-I is produced in E.coli using a patented expression system and the IGF-I is correctly folded and purified by several chromatography steps to yield Receptor Grade IGF-I.
Human LR3 insulin-like Growth Factor-I (LR3IGF-I) is an 83 amino acid analogue of IGF-I comprising the complete human IGF-I sequence with the substitution of an Arginine for the Glutamine at position 3, plus a 13 amino acid extension peptide at the N-terminus.
Human LR3IGF-I is more potent than IGF-I in vitro and in vivo. This increased potency is due to reduced binding of LR3IGF-I to most of the IGF binding proteins which modify the biological actions of IGF-I. Human LR3IGF-I binds to the type 1 IGF receptor with similar affinity to wild type IGF-I.
LR3IGF-I was developed by GroPep specifically for supplementation of mammalian cell culture to support the survival and proliferation of cells. It is engineered to have a higher biological potency than native IGF-I or IGF-II and has several advantages over recombinant insulin. Supplementation of cell cultures with LR3IGF-I at a much lower concentration results in equivalent or better productivity than supplementation with standard concentrations of insulin. LR3IGF-I is better able to stimulate the type I IGF receptor and thus induce a higher level of activation of intracellular signalling molecules which are responsible for promoting cell survival by inhibition of apoptosis.
- Purity: >95 %
- Quantity: 100 µg
- Molecular Weight: 9110.6±2 Daltons – confirmed by Mass Spectrometry
- N-terminal sequence analysis of recombinant product: Analysis of 18 residues
- Biological Activity: Proliferation of Chinese Hamster Ovary (CHO) cells (ED50 < 350 ng/ml)
- Endotoxin (LAL): <0.1 EU/ug
- Storage/Stability: At least 2 years at 2-8°C (lyophilized)
- Appearance: White Powder
- State: Dried from 0.1 M acetic acid under dry nitrogen at a slight vacuum